Get started
Author

Roisin Puentes

Observed name: Puentes Roisin
ORCID: 0000-0003-4187-2043
Observed ORCID: 0000-0003-4187-2043
OpenAlex ID: A5008861381
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
2019 · Martin Indarte, Roisin Puentes, et al. · Cancer Research · 37
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system
2023 · Veronica C. Shim, Robin J. Baker, et al. · Breast Cancer Research and Treatment · 12
PDF
PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer
2021 · Hei-Cheul Jeung, Roisin Puentes, et al. · Experimental Cell Research · 9
Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma
2024 · Xiao Huang, Sarah A. Anderson, et al. · Clinical Breast Cancer · 7
Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US.
2025 · Thomas C. Krivak, Roisin Puentes, et al. · Journal of Clinical Oncology · 4
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
2019 · Martin Indarte, Roisin Puentes, et al. · Cancer Research · 1
Real-world evidence for comprehensive genomic profiling in myeloid malignancies: Changes in detection and clinical impact.
2026 · Madhuri Paul, Roisin Puentes, et al. · Journal of Clinical Oncology
Abstract 1993: Real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies (2020-2025).
2026 · Roisin Puentes, Madhuri Paul, et al. · Cancer Research
Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis
2025 · John M. Furgason, Timothy J. Stuhlmiller, et al. · Blood
The cancer fusionome and overexpressed druggable oncogenic signals in K-RAS wild-type pancreatic cancer.
2025 · Michal Krawczyk, Roisin Puentes, et al. · Journal of Clinical Oncology
Genetic Insights into Myeloid Malignancies: A Comparative Analysis of NCCN Guidelines, the World Health Organization Classification, and the ICC System
2024 · Roisin Puentes, Jonathan Feld, et al. · Blood
Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples.
2024 · Chaugiang Duong, Roisin Puentes, et al. · Journal of Clinical Oncology
PDF
A study of the gaps and opportunities with fusion detection beyond NTRKs on 422 patients from the community.
2024 · Hatim Husain, Chaugiang Duong, et al. · Journal of Clinical Oncology
PDF
Supplemental Information from An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
2023 · Martin Indarte, Roisin Puentes, et al.
Data from An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors
2023 · Martin Indarte, Roisin Puentes, et al.
Works count: 15
Citation count: 70
H-index: 4
I10-index: 2
Year
Topic
Type